Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $7.90 Analyst target: $240.00 Upside: 2937.97%
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant viruses and tumors in the United States. The company is headquartered in Houston, Texas.
See the full interactive analysis & chart →Informational only — not investment advice.